----

----

| Delaware                                                      |   | 20-1499421                       |
|---------------------------------------------------------------|--------|----------------------------------|
| (State or Other Jurisdictionof Incorporation or Organization) |   | (IRS EmployerIdentification No.) |
|                                                          |   |                             |
| 10757 South River Front Pkwy, Suite 125                       |   |                             |
| South Jordan, Utah                                            |   | 84095                            |
| (Address of Principal Executive Offices)                      |   | (Zip Code)                       |

|   | (801) 816-2533                                       |   |
|--------|------------------------------------------------------|--------|
|   | Issuer’s Telephone Number, Including Area Code |   |
|   |                                                 |   |

----

----

Table of Contents

| ITEM 1. | FINANCIAL STATEMENTS REQUIRED BY FORM 10-Q |
|---------|--------------------------------------------|

----

Table of Contents

| CONTENTS                                 |
|-----------------------------------------------|
| Balance Sheets                      | 5 |
| Statements of Operations            | 6 |
| Statements of Cash Flows                 | 7 |
| Notes to the Financial Statements   | 8 |

----

Table of Contents

| NANO DIMENSIONS, INC.                                                      |   |
|----------------------------------------------------------------------------|--------|
| (formerly Cancer Therapeutics, Inc.)                                       |   |
| Balance Sheets                                                             |   |
|                                                                       |   |   |   |   |   |   |
|                                                                       |   |   |   |   |   |   |
| ASSETS                                                                     |   |
|                                                                       |   | November 30, |   |   | May 31, |   |
|                                                                       |   | 2010 |   |   | 2010 |   |
|                                                                       |   | (Unaudited) |   |   |   |   |
|                                                                       |   |   |   |   |   |   |
| CURRENT ASSETS                                                             |   |   |   |   |   |   |
|                                                                       |   |   |   |   |   |   |
| Cash and cash equivalents                                                  |   | $ | 118 |   |   | $ | 33,686 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| Total Current Assets                                                       |   |   | 118 |   |   |   | 33,686 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| OTHER ASSETS                                                               |   |   |   |   |   |   |   |   |
|                                                                       |   |   |   |   |   |   |   |   |
| Notes receivable                                                           |   |   | 61,000 |   |   |   | 61,000 |   |
| Interest receivable                                                        |   |   | 3,249 |   |   |   | 802 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| Total Other Assets                                                         |   |   | 64,249 |   |   |   | 61,802 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| TOTAL ASSETS                                                               |   | $ | 64,367 |   |   | $ | 95,488 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS' DEFICIT                                      |   |
|                                                                       |   |   |   |   |   |   |   |   |
| CURRENT LIABILITIES                                                        |   |   |   |   |   |   |   |   |
|                                                                       |   |   |   |   |   |   |   |   |
| Accounts payable and accrued expenses                                      |   | $ | 120,477 |   |   | $ | 124,763 |   |
| Due to related party                                                       |   |   | 17,500 |   |   |   | 18,250 |   |
| Other accrued expenses                                                     |   |   | 150,000 |   |   |   | 150,000 |   |
| Notes payable                                                              |   |   | 100,000 |   |   |   | 100,000 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| Total Current Liabilities                                                  |   |   | 387,977 |   |   |   | 393,013 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| TOTAL LIABILITIES                                                          |   |   | 387,977 |   |   |   | 393,013 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| STOCKHOLDERS' DEFICIT                                                      |   |   |   |   |   |   |   |   |
|                                                                       |   |   |   |   |   |   |   |   |
| Preferred stock, $0.001 par value; 20,000,000 shares                       |   |   |   |   |   |   |   |   |
|  authorized, 200 and 200 shares issued and                            |   |   |   |   |   |   |   |   |
|  outstanding, respectively                                            |   |   | - |   |   |   | - |   |
| Common stock, $0.001 par value; 500,000,000 shares                         |   |   |   |   |   |   |   |   |
|  authorized, 171,139 and 171,139 shares issued,                       |   |   |   |   |   |   |   |   |
|  respectively                                                         |   |   | 171 |   |   |   | 171 |   |
| Treasury stock, 56 shares                                                  |   |   | (14,105 | ) |   |   | (14,105 | ) |
| Additional paid-in capital                                                 |   |   | 3,560,036 |   |   |   | 3,560,036 |   |
| Accumulated deficit                                                        |   |   | (3,869,712 | ) |   |   | (3,843,627 | ) |
|                                                                       |   |   |   |   |   |   |   |   |
| Total Stockholders' Deficit                                                |   |   | (323,610 | ) |   |   | (297,525 | ) |
|                                                                       |   |   |   |   |   |   |   |   |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT                                |   | $ | 64,367 |   |   | $ | 95,488 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| The accompanying notes are an integral part of these financial statements. |   |
|                                                                       |   |   |   |   |   |   |   |   |

----

Table of Contents

| NANO DIMENSIONS, INC.                                                      |   |
|----------------------------------------------------------------------------|--------|
| (formerly Cancer Therapeutics, Inc.)                                       |   |
| Statements of Operations                                                   |   |
| (Unaudited)                                                                |   |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                       |   | For the Three Months Ended |   |   | For the Six Months Ended |   |
|                                                                       |   | November 30, |   |   | November 30, |   |
|                                                                       |   | 2010 |   |   | 2009 |   |   | 2010 |   |   | 2009 |   |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |
| NET REVENUES                                                               |   | $ | - |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| OPERATING EXPENSES                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consulting                                                                 |   |   | - |   |   |   | 96,845 |   |   |   | - |   |   |   | 203,689 |   |
| Professional fees                                                          |   |   | 12,210 |   |   |   | 12,096 |   |   |   | 15,320 |   |   |   | 30,739 |   |
| General and administrative                                                 |   |   | 4,509 |   |   |   | 1,247 |   |   |   | 9,138 |   |   |   | 7,800 |   |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Total Operating Expenses                                                   |   |   | 16,719 |   |   |   | 110,188 |   |   |   | 24,458 |   |   |   | 242,228 |   |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| LOSS FROM OPERATIONS                                                       |   |   | (16,719 | ) |   |   | (110,188 | ) |   |   | (24,458 | ) |   |   | (242,228 | ) |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| OTHER INCOME (EXPENSES)                                                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Interest income                                                            |   |   | 1,217 |   |   |   | - |   |   |   | 2,447 |   |   |   | - |   |
| Loss on investment                                                         |   |   | - |   |   |   | (2,010 | ) |   |   | - |   |   |   | (3,350 | ) |
| Interest expense                                                           |   |   | (2,026 | ) |   |   | (1,324 | ) |   |   | (4,074 | ) |   |   | (2,364 | ) |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Total Other Income (Expenses)                                              |   |   | (809 | ) |   |   | (3,334 | ) |   |   | (1,627 | ) |   |   | (5,714 | ) |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| LOSS BEFORE INCOME TAXES                                                   |   |   | (17,528 | ) |   |   | (113,522 | ) |   |   | (26,085 | ) |   |   | (247,942 | ) |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| INCOME TAX EXPENSE                                                         |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| NET LOSS                                                                   |   | $ | (17,528 | ) |   | $ | (113,522 | ) |   | $ | (26,085 | ) |   | $ | (247,942 | ) |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| BASIC AND FULLY DILUTED:                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss per common share                                                  |   | $ | (0.10 | ) |   | $ | (0.66 | ) |   | $ | (0.15 | ) |   | $ | (1.45 | ) |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Weighted average shares outstanding                                        |   |   | 171,083 |   |   |   | 171,083 |   |   |   | 171,083 |   |   |   | 171,000 |   |
|                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| The accompanying notes are an integral part of these financial statements. |   |

----

Table of Contents

| NANO DIMENSIONS, INC.                                                      |   |
|----------------------------------------------------------------------------|--------|
| (formerly Cancer Therapeutics, Inc.)                                       |   |
| Statements of Cash Flows                                                   |   |
| (Unaudited)                                                                |   |
|                                                                       |   |   |   |   |   |   |
|                                                                       |   | For the Six Months Ended |   |
|                                                                       |   | November 30, |   |
|                                                                       |   | 2010 |   |   | 2009 |   |
|                                                                       |   |   |   |   |   |   |
| CASH FLOWS FROM OPERATING ACTIVITIES:                                      |   |   |   |   |   |   |
|                                                                       |   |   |   |   |   |   |
| Net loss                                                                   |   | $ | (26,085 | ) |   | $ | (247,942 | ) |
| Adjustments to reconcile net loss to net                                   |   |   |   |   |   |   |   |   |
|  cash used by operating activities:                                   |   |   |   |   |   |   |   |   |
| Amortization of prepaid services for stock                                 |   |   | - |   |   |   | 193,689 |   |
| Loss on investment in subsidiary                                           |   |   | - |   |   |   | 3,350 |   |
| Changes in operating assets and liabilities:                               |   |   |   |   |   |   |   |   |
| Interest receivable                                                        |   |   | (2,447 | ) |   |   | - |   |
| Accounts payable and accrued expenses                                      |   |   | (4,286 | ) |   |   | (4,417 | ) |
| Due to related party                                                       |   |   | (750 | ) |   |   | - |   |
|                                                                       |   |   |   |   |   |   |   |   |
| Net Cash Used by Operating Activities                                      |   |   | (33,568 | ) |   |   | (55,320 | ) |
|                                                                       |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES:                                      |   |   |   |   |   |   |   |   |
|                                                                       |   |   |   |   |   |   |   |   |
| Investment in subsidiary                                                   |   |   | - |   |   |   | (50,000 | ) |
| Cash payments for loans receivable - related party                         |   |   | - |   |   |   | (3,445 | ) |
|                                                                       |   |   |   |   |   |   |   |   |
| Net Cash Used by Investing Activities                                      |   |   | - |   |   |   | (53,445 | ) |
|                                                                       |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES:                                      |   |   |   |   |   |   |   |   |
|                                                                       |   |   |   |   |   |   |   |   |
| Proceeds from notes payable                                                |   |   | - |   |   |   | 50,000 |   |
| Proceeds from exercise of stock warrants                                   |   |   | - |   |   |   | 59,000 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| Net Cash Provided by Financing Activities                                  |   |   | - |   |   |   | 109,000 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| NET INCREASE (DECREASE) IN CASH AND                                        |   |   |   |   |   |   |   |   |
|  CASH EQUIVALENTS                                                     |   |   | (33,568 | ) |   |   | 235 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD                             |   |   | 33,686 |   |   |   | 760 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| CASH AND CASH EQUIVALENTS, END OF PERIOD                                   |   | $ | 118 |   |   | $ | 995 |   |
|                                                                       |   |   |   |   |   |   |   |   |
| SUPPLEMENTAL CASH FLOW INFORMATION:                                        |   |   |   |   |   |   |   |   |
|                                                                       |   |   |   |   |   |   |   |   |
| Cash Payments For:                                                         |   |   |   |   |   |   |   |   |
| Interest                                                                   |   | $ | - |   |   | $ | - |   |
| Income taxes                                                               |   | $ | - |   |   | $ | - |   |
|                                                                       |   |   |   |   |   |   |   |   |
| The accompanying notes are an integral part of these financial statements. |   |

----

Table of Contents

Notes to the Financial Statements

| NOTE 2 - | BASIS OF FINANCIAL STATEMENT PRESENTATION |
|----------|-------------------------------------------|

|   | The accompanying unaudited financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations.  The information furnished in the interim financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements.  Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and notes thereto included in its Form 10K filed on September 14, 2010.  Operating results for the six months ended November 30, 2010 are not necessarily indicative of the results to be expected for the year ending May 31, 2011. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|                                                         |   | November 30,2010 |   |   | May 31,2010 |    |
|--------------------------------------------------------------|--------|------------------|--------|--------|-------------|---------|
| Note receivable from a company, 8.0% interest, due on demand |   |  $          | 61,000 |   |        |  $ | 61,000 |   |
| Total Notes Receivable                                       |   |             | 61,000 |   |        |    | 61,000 |   |
| Less: Current Portion                                        |   |             | -      |   |        |    | - |   |
| Long Term Notes Receivable                                   |   |  $          | 61,000 |   |        |  $ | 61,000 |   |

| NOTE 5 - | ACCOUNTS PAYABLE AND ACCRUED EXPENSES |
|----------|---------------------------------------|

|   | The Company’s accounts payable and accrued expenses balance includes accrued interest of $19,808 and $15,734 as of November 30, 2010 and May 31, 2010, respectively.  This interest primarily relates to notes payable.  The Company also has accrued for unpaid payroll taxes for the fiscal years ended May 31, 2010 and 2009 in the amount of $42,249.  As of November 30, 2010 and May 31, 2010, the Company has accrued an additional $27,895 as an estimate of penalties and interest relating to this balance.  Both of these amounts are included in accounts payable and accrued expenses. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|                                                                                                                                                                                |   | November 30,2010 |   |   | May 31,2010 |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------|--------|--------|-------------|---------|
| Amount due to Chene Gardner, chief executive officer and chief financial officer of the Company, for unpaid accounting and management services, non-interest bearing, due on demand |   |  $          | 17,500 |   |        |  $ | 18,250 |   |
| Total                                                                                                                                                                               |   |  $          | 17,500 |   |        |  $ | 18,250 |   |

|                                                                                                                                 |   | November 30,2010 |                 |   | May 31,2010 |    |
|--------------------------------------------------------------------------------------------------------------------------------------|--------|------------------|----------------------|--------|-------------|---------|
| Note payable to a bank, 8.25% interest,matured December 31, 2005, securedby tangible and intangible assets of theCompany, in default |   |  $          |     50,000 |   |        |  $ |     50,000 |   |
| Note payable to a company, 8.0% interest,matured November 3, 2010, unsecured, in default                                             |   |             | 50,000               |   |        |    | - |   |
| Total Notes Payable                                                                                                                  |   |             | 100,000              |   |        |    | 50,000 |   |
| Less: Current Portion                                                                                                                |   |             | (100,000             | )      |        |    | (50,000 | ) |
| Long Term Notes Payable                                                                                                              |   |  $          | -                    |   |        |  $ | - |   |

----

Table of Contents

|                             |   | Number of Shares |   |   | Weighted Average Exercise Price |   |
|----------------------------------|--------|------------------|--------|--------|---------------------------------|--------|
| Outstanding as of May 31, 2009   |   |             | 36,850 |   |                            | $      | 50.00 |   |
| Granted                          |   |             | -      |   |                            |   | - |   |
| Exercised                        |   |             | (1,180 | )      |                            |   | (50.00 | ) |
| Expired                          |   |             | -      |   |                            |   | - |   |
| Outstanding at May 31, 2010      |   |             | 35,670 |   |                            | $      | 50.00 |   |
| Granted                          |   |             | -      |   |                            |   | - |   |
| Exercised                        |   |             | -      |   |                            |   | - |   |
| Cancelled                        |   |             | -      |   |                            |   | - |   |
| Outstanding at November 30, 2010 |   |             | 35,670 |   |                            | $      | 50.00 |   |

----

Table of Contents

|         |   | Warrants Outstanding |   |   | Warrants Exercisable      |   |
|--------------|--------|----------------------|--------|--------|---------------------------|--------|
| Year Granted |   | Exercise Price       |   |   | Number shares outstanding |   |   | Weighted Average Contractual Life (Years) |   |   | Number Exercisable |   |   | Weighted Average Exercise Price |   |
|         |   |                 |   |   |                      |   |   |   |   |   |   |   |   |   |   |
| 2009         |   | $                    | 50.00  |   |                      |   | 35,670 |   |   |   | 5.00 |   |   |   | 35,670 |   |   | $ | 50.00 |   |
| Total        |   |                 |   |   |                      |   | 35,670 |   |   |   |   |   |   |   | 35,670 |   |   |   |   |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
|---------|-------------------------------------------------------------|

| ITEM 3. | DEFAULTS UPON SENIOR SECURITIES |
|---------|---------------------------------|

| ITEM 4. | SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS |
|---------|-----------------------------------------------------|

| ITEM 5. | OTHER INFORMATION |
|---------|-------------------|

| ITEM 6. | EXHIBITS |
|---------|----------|

----

Table of Contents

| ExhibitNumber |   |  Title of Document                                                                                                                         |
|---------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1           |   | Restated Certificate of Incorporation of Nano Dimensions, Inc., a Delaware corporation. (1)                                                |
| 3.2           |   | Bylaws of Nano Dimensions, Inc., a Delaware corporation. (2)                                                                               |
| 23.1          |   | Consent of Bouwhuis, Morrill and Company, LLC. (8)                                                                                         |
| 23.2          |   | Consent of Kenneth I. Denos, P.C. (Filed as part of Exhibit 5.1). (9)                                                                      |
| 31            |   | Certification by Chief Executive Officer and Chief Financial Officer, Chene Gardner, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32            |   | Certification by Chief Executive Officer and Chief Financial Officer, Chene Gardner, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |

| (1)   | Filed as an Exhibit to the Company’s Form 8-K filed with the Commission on October 25, 2010. |
|-----------------|----------------------------------------------------------------------------------------------------|

| (2)   | Filed as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed effective by the Commission on May 15, 2006. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------|

| (3)   | Filed as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed effective by the Commission on May 15, 2006. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------|

| (4)   | Filed as an Exhibit to the Company’s Registration Statement on Form SB-2, deemed effective by the Commission on May 15, 2006. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|                   | NANO DIMENSIONS, INC.   |
|------------------------|-------------------------|
|                   |                    |
| Date: January 17, 2010 | BY: /S/ Chene Gardner   |
|                   | Chene Gardner           |
|                   | Chief Executive Officer |

----

Table of Contents